Document Detail

Cutaneous toxicities of RAF inhibitors.
MedLine Citation:
PMID:  23276366     Owner:  NLM     Status:  MEDLINE    
The RAF inhibitors vemurafenib and dabrafenib are emerging as the standard of care for Val600 BRAF-mutant metastatic melanoma. These drugs have shown clinical benefit over the standard care (dacarbazine); however, they are associated with frequent cutaneous adverse events, which can be concerning to the patient and their physician. Herein, we review the range of cutaneous disorders that seem to be induced by RAF inhibitors, including cutaneous squamous-cell carcinoma, hyperkeratotic lesions, Grover's disease, keratosis pilaris-like reactions, and photosensitivity. These disorders often affect patients' quality of life; therefore, dermatological assessment and timely management is essential to ensure that patients continue to use RAF inhibitors.
Rachael Anforth; Pablo Fernandez-Peñas; Georgina V Long
Related Documents :
15665256 - Use of cellular and plasma apheresis in the critically ill patient: part 1: technical a...
23112666 - Canoe: a context-aware notification model to support the care of older adults in a nurs...
20688876 - Nationwide acute care physical therapist practice analysis identifies knowledge, skills...
8290616 - Physical therapy episodes of care for patients with low back pain.
25177486 - Total joint perioperative surgical home: an observational financial review.
21278636 - Retrospective study of pressure ulcer prevalence in dutch general hospitals since 2001.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  The Lancet. Oncology     Volume:  14     ISSN:  1474-5488     ISO Abbreviation:  Lancet Oncol.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-01-01     Completed Date:  2013-04-03     Revised Date:  2014-08-18    
Medline Journal Info:
Nlm Unique ID:  100957246     Medline TA:  Lancet Oncol     Country:  England    
Other Details:
Languages:  eng     Pagination:  e11-8     Citation Subset:  IM    
Copyright Information:
Copyright © 2013 Elsevier Ltd. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Abnormalities, Multiple / chemically induced
Acantholysis / chemically induced,  pathology,  therapy
Antineoplastic Agents / administration & dosage,  adverse effects
Clinical Trials as Topic
Darier Disease / chemically induced
Eyebrows / abnormalities
Ichthyosis / chemically induced,  pathology,  therapy
Imidazoles / administration & dosage,  toxicity*
Indoles / administration & dosage,  toxicity*
Keratosis / chemically induced,  pathology,  therapy
Melanoma* / drug therapy,  pathology
Oximes / administration & dosage,  toxicity*
Photosensitivity Disorders / chemically induced,  pathology,  therapy
Proto-Oncogene Proteins B-raf* / antagonists & inhibitors,  genetics
Sulfonamides / administration & dosage,  toxicity*
Reg. No./Substance:
0/Antineoplastic Agents; 0/Imidazoles; 0/Indoles; 0/Oximes; 0/PLX4032; 0/Sulfonamides; EC protein, human; EC Proteins B-raf; QGP4HA4G1B/dabrafenib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  New clinical classification system for atlantoaxial dislocation.
Next Document:  Molecular diagnostics in paediatric glial tumours.